Stock Comparison

ABBV vs TWST

AbbVie Inc vs Twist Bioscience Corp

The Verdict

TWST takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

TWST

Twist Bioscience Corp

7.0

out of 10

Solid Pick

Head-to-Head

$381.1B

Market Cap

$4.2B

104.8

P/E Ratio

14.7

5.8%

Profit Margin

-19.9%

95.6%

Return on Equity

-17.5%

20.2

Debt-to-Equity

0.5

Moderate

Overall Risk

Aggressive

0.1

DVR Score

7.0

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

TWST7.0/10

Twist Bioscience maintains its high-risk, high-reward profile with compelling 10x growth potential, driven by its unique silicon-based DNA synthesis platform and strategic entry into DNA data storage. Q2 FY26 results confirmed strong revenue growth and expanded clonal gene offerings, reinforcing its market opportunity and technological moat. However, the reported EPS miss for Q2 FY26 and ongoing i...

Full TWST Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.